Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia
Phase 2 Recruiting
80 enrolled
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
Phase 2 Recruiting
40 enrolled
Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Phase 2 Recruiting
44 enrolled
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Phase 2 Recruiting
100 enrolled
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
Phase 2 Recruiting
40 enrolled
A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma
Phase 2 Recruiting
49 enrolled
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
Phase 2 Recruiting
65 enrolled
ACCELERATE
Phase 2 Recruiting
358 enrolled
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
Phase 2 Recruiting
33 enrolled
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
Phase 2 Recruiting
35 enrolled
Odronextamab in Low Tumor Volume Advanced FL
Phase 2 Recruiting
35 enrolled
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Phase 2 Recruiting
41 enrolled
A Study of Mogamulizumab to Prevent Adult T-cell Leukemia/Lymphoma in People With HTLV-1
Phase 2 Recruiting
134 enrolled
MZL-IIT-O
Phase 2 Recruiting
30 enrolled
Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma
Phase 2 Recruiting
83 enrolled
BRAZAN
Phase 2 Recruiting
60 enrolled
Epco, Zanu, Ritux for R/R FL or MZL
Phase 2 Recruiting
45 enrolled
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
Phase 2 Recruiting
40 enrolled
Venetoclax and Decitabine in R/R T-ALL
Phase 2 Recruiting
28 enrolled
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Phase 2 Recruiting
36 enrolled
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
Phase 2 Recruiting
30 enrolled
A Study of Response Adapted Ultra Low Dose 4 Gy Radiation for Definitive Therapy of Marginal Zone Lymphoma
Phase 2 Recruiting
50 enrolled
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
Phase 2 Recruiting
152 enrolled
FIL_DALYA
Phase 2 Recruiting
28 enrolled
Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma
Phase 2 Recruiting
12 enrolled
IMCL-2023
Phase 2 Recruiting
50 enrolled
FIL_Tisle-HL
Phase 2 Recruiting
28 enrolled
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
Phase 2 Recruiting
30 enrolled
MALMBA
Phase 2 Recruiting
20 enrolled
VIWA-1
Phase 2 Recruiting
80 enrolled
LATE-R-GEL-23
Phase 2 Recruiting
45 enrolled
Benefit VA
Phase 2 Recruiting
100 enrolled
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma
Phase 2 Recruiting
20 enrolled
REPIFIR
Phase 2 Recruiting
80 enrolled
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Phase 2 Recruiting
300 enrolled
Isatuximab During Stem Cell Collection and Transplant in Patients With Multiple Myeloma and Lymphoma
Phase 2 Recruiting
39 enrolled
EpLCART
Phase 2 Recruiting
40 enrolled
ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis
Phase 2 Recruiting
20 enrolled
Selinexor, High-dose Methotrexate, and Rituximab Combined With Radiotherapy for Newly Diagnosed, Transplant-ineligible Patients With Central Nervous System Lymphoma: An Open-label, Single-arm, Multicenter Phase II Study
Phase 2 Recruiting
26 enrolled
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma
Phase 2 Recruiting
120 enrolled
Assessment of the Safety and Efficacy of Balstilimab for the Treatment of Relapsed/Refractory Lymphomas (IMMONC0001)
Phase 2 Recruiting
20 enrolled
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
Phase 2 Recruiting
30 enrolled
DALY II USA/ MB-CART2019.1 for DLBCL
Phase 2 Recruiting
248 enrolled
LORELY
Phase 2 Recruiting
50 enrolled
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma
Phase 2 Recruiting
30 enrolled
VHAG in Treating R/R T-ALL/LBL
Phase 2 Recruiting
50 enrolled
EPBSCH
Phase 2 Recruiting
46 enrolled
PRONTO
Phase 2 Recruiting
100 enrolled
Concurrent Tislelizumab and Radiotherapy in Newly Diagnosed Extranodal NK/T-cell Lymphoma, Nasal Type
Phase 2 Recruiting
38 enrolled
REFRACT
Phase 2 Recruiting
284 enrolled